UK-VYEP-1007 | June 2026
UK-VYEP-1008 | June 2026
GIVE YOUR PATIENTS
THE CONFIDENCE TO DO WHAT THEY LOVE,
WHEREVER THEY ARE.
VYEPTI® (eptinezumab) is an anti-CGRP monoclonal antibody indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1 VYPETI is administered via one 30-minute intravenous infusion, every 12 weeks.1 Explore the questions below to find out more about how VYEPTI could help your patients.
?>
Who are the
?>
What are the
?>
How does
?>
What is the
?>
How soon after
?>
When in the
?>
How does
?>
What needs to be
Who are the
right patients
or VYEPTI?
What are the
benefits of
VYEPTI IV?
How does
VYEPTI work?
What is the
clinical evidence
for VYEPTI?
How soon after
infusion does VYEPTI
start working?
When in the
treatment pathway
should VYEPTI be used?
How does
VYEPTI impact
quality of life?
What needs to be
considered when
administering VYEPTI IV?
CONTACT US
LET'S
CONNECT
Schedule a meeting about VYEPTI with your local Lundbeck representative
HERE
TO HELP
Contact us with any general or
product-related queries
STAY
IN TOUCH
To receive information and
updates about VYEPTI,
sign up for promotional
communications from Lundbeck
